Monday, November 5, 2007

Trasyslol Attorney | Trasylol Lawyer

A commonly used drug during heart surgery could cause serious complications including kidney damage, an increased risk of heart attack, heart failure and stroke. The drug called Trasylol, which has been on the market for 13 years, is used to control bleeding on as many as 1 million heart and bypass surgery patients per year.

Trasylol doubles the risk of kidney damage but also increases the risk of heart attack by 48%. Heart failure risk is also increased by 109% and stroke by 181%. Because it is given intravenously, most people do not even know that they are receiving it. If you or someone you know experienced kidney problems, heart attack, or stroke following heart surgery, contact us to speak with an attorney for a free case evaluation or contact us online.

Serious Risks: Trasylol or Aprotinin

On January 26, 2006, the New England Journal of Medicine published a study of 4,374 Heart Bypass surgery patients with regard to the use of Trayslol (Aprotinin), which is Bayer's inject-able drug used to prevent excessive blood loss during surgery.
The study was started because the medical and surgical treatments of heart attacks were contradictory.

Medical treatment uses clot-dissolving agents and a class of drugs that inhibit clotting to forestall further heart attacks.Surgical treatment for heart attacks uses drugs such as Aprotinin to promote clot formation to prevent internal bleeding.The results of the study published are:
Use of Trasylol / Aprotinin for heart surgery to control bleeding doubles the risk of kidney damageResultant kidney damage forces an estimated 10,000 patients onto kidney dialysis each yearRisk of heart attack is increased 48 percent with the use of Trasylol / AprotininRisk of heart failure is increased 109 percent with the use of Trasylol / AprotininRisk of stroke is increased 181 percent with the use of Trasylol / AprotininAccording to an article published in the Los Angeles Times, January 25, 2006, Dr. Dennis T. Mangano of the Ischemia Research and Education Foundation who led the study is quoted as saying: "But isn't the patient who received Aprotinin likely " to have a heart-attack-induced-clot? "It seems very logical."

FDA Issues Trasylol Warning!

The FDA issued a health advisory on February 8, 2006, in which it warned the public of the increased risk of kidney failure, heart attack, and stroke in patients who were given Trasylol and undergo artery bypass graft surgery.

Alternative Drugs Available - Safe & Less Expensive

The Study concluded that there are 2 other generic drugs that are safer and less expensive than Trasylol. While Trasylol cost is $1,300 per dose, the generic, Amicar is $11 per dose and the generic drug, Cyklokapron is $44 per dose. Neither of the generic drugs were associated with increased renal, cardiac or cerebral events. According to a bulletin published January 27, 2006, by the Washington Business Information, Inc., Replacing Aprotinin with one of the two safe generic drugs, would:

Prevent as many as 11,000 kidney dialysis complications per yearSave approximately 1 billion dollars in kidney dialysis costs per yearReduce heart attack and kidney treatment drug costs by at least $250 million per year